A case of palmoplantar pustulosis induced by certolizumab pegol: New anti-TNF-alpha demonstrates the same class effect

Journal of Clinical and Aesthetic Dermatology

Volumn 5, Issue 8, 2012, Pages 40-41

  Shelling, Michael L ^a   Vitiello, Magalys ^a   Lanuti, Emma L ^a   Miteva, Maria ^a   Romanelli, Paolo ^a   Kerdel, Francisco A ^a  

^a UNIVERSITY OF MIAMI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; ETANERCEPT; METHOTREXATE; STEROID;

AGED; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; FEVER; HUMAN; MALAISE; MALE; PUSTULE; PUSTULOSIS PALMOPLANTARIS; RHEUMATOID ARTHRITIS; SKIN BIOPSY;

EID: 84866255897     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Moustou AE, Matekovits A, Dessinioti C, et al. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009 Jul 21. Epub ahead of print.
2. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68(2):209-215. Epub 2008 Apr 2.
3. Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9(1):1-14.
4. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68:805-811.
5. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233-240.
6. Cohen JD, Bournerias I, Buffard V, et al. Psoriasis induced by tumor necrosis factor-• antagonist therapy: a case series. J Rheumatol. 2007;34:380-385.